血管生成在疾病治疗中的应用与展望

doi:10.6040/j.issn.1671-7554.0.2021.0936

摘要/Abstract

摘要： 血管生成与新生参与了许多疾病的发生、演变和进展,包括最常见和致命性心血管疾病、癌症、糖尿病、炎症及眼科疾病等。促进或抑制血管生成已经成为上述疾病的重要治疗策略。截至撰写本文时,许多靶向血管生成的药物已经获得了不同国家食品药品监督管理局的批准,用于治疗恶性疾病和眼科疾病。本文将介绍血管生成参与疾病进展的机制、靶向血管生成的新型治疗策略及其在临床应用中的挑战与展望。

关键词: 血管生成, 肿瘤, 眼科疾病, 心脑血管疾病, 代谢性疾病, 新型冠状病毒肺炎

Abstract: Angiogenesis, the process of new blood vessel growth, is involved in the onset, development and progression of a number of human diseases, including the most common and lethal disorders such as cardiovascular disease, cancer, diabetes, inflammatory disease, and eye disease. Interference of angiogenesis by either enhancement or suppression provides exciting and important therapeutic approaches for treatment of these and other diseases. So far, a number of drugs targeting angiogenesis have received approvals from the FDA authorities in various countries for treatment of malignant and ophthalmological diseases. This article aims to provide mechanistic insights into angiogenesis in diseases, new therapeutic options, and therapeutically challenging issues in the clinic.

Key words: Angiogenesis, Cancer, Eye disease, Cerebrocardiovascular disease, Metabolic disease, COVID-19

中图分类号:

R732.2

曹义海. 血管生成在疾病治疗中的应用与展望[J]. 山东大学学报 (医学版), 2021, 59(9): 9-14.

CAO Yihai. Targeting angiogenesis for disease therapy[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 9-14.

参考文献

[1] Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971, 285(21): 1182-1186.
[2] Cao Y. Off-tumor target - beneficial site for antiangiogenic cancer therapy? [J]. Nat Rev Clin Oncol, 2010, 7(10): 604-608.
[3] Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs [J]. Nat Rev Endocrinol, 2014, 10(9): 530-539.
[4] Cao Y, Arbiser J, DAmato RJ, et al. Forty-year journey of angiogenesis translational research [J]. Sci Transl Med, 2011, 3(114): 114rv113. doi: 10.1126/scitranslmed.3003149.
[5] Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis [J]. Sci Transl Med, 2010, 2(15): 15ps13. doi: 10.1126/scitranslmed.3000399.
[6] Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors [J]. Nat Med, 2003, 9(6): 669-676.
[7] Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands [J]. Science signaling, 2009, 2(59): re1. doi: 10.1126/scisignal.259re1.
[8] Cao Y, Linden P, Farnebo J. et al. Vascular endothelial growth factor C induces angiogenesis in vivo [J]. Proc Natl Acad Sci USA, 1998, 95(24): 14389-14394.
[9] Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C [J]. EMBO J, 1997, 16(13): 3898-3911.
[10] Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J]. Nature, 1996, 380(6573): 439-442.
[11] Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J]. Nature, 1996, 380(6573): 435-439.
[12] OReilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice [J]. Nature medicine, 1996, 2(6): 689-692.
[13] Cao Y, OReilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases [J]. J Clin Invest, 1998, 101(5): 1055-1063.
[14] Gimbrone Jr MA, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo by prevention of neovascularization [J]. J Exp Med, 1972, 136(2): 261-276.
[15] Folkman J. Tumor angiogenesis and tissue factor [J]. Nature medicine, 1996, 2(1996): 167-168.
[16] Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid [J]. Science, 1983, 219(4587): 983-985.
[17] Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen [J]. Science, 1989, 246(4935): 1306-1309.
[18] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23):2335-2342.
[19] Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer [J]. Lancet, 2016, 388(10060): 2654-2664.
[20] Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy(REVEL): a multicentre, double-blind, randomised phase 3 trial [J]. Lancet, 2014, 384(9944): 665-673.
[21] Cao Y. Obesity Protects Cancer from Drugs Targeting Blood Vessels [J]. Cell Metab, 2018, 27(6): 1163-1165.
[22] Iwamoto H, Abe M, Yang Y, et al. Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance [J]. Cell Metab, 2018, 28(1): 104-117.
[23] OReilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth [J]. Cell, 1997, 88(2): 277-285.
[24] OReilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994, 79(2): 315-328.
[25] Li Y, Huang P, Peng H, et al. Antitumor effects of Endostar(rh-endostatin)combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma [J]. Cancer Manag Res, 2019, 11: 3469-3479. doi: 10.2147/CMAR.S192868. eCollection 2019.
[26] Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy [J]. Nat Rev Drug Discov, 2016, 15(6): 385-403.
[27] Adamis AP, Ehrlich J, Fung A. Targeting the Effect of VEGF in Diabetic Macular Edema [J]. N Engl J Med, 2015, 373(5): 480-481.
[28] DAmico DJ, Masonson HN, Manju Patel, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials [J]. Ophthalmology, 2006, 113(6): 992-1001.
[29] Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha [J]. Nature, 2008, 451(7181): 1008-1012.
[30] Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression [J]. Nature, 2001, 414(6863): 550-554.
[31] LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium [J]. Nature, 2001, 412(6850): 877-884.
[32] Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration [J]. N Engl J Med, 2004, 351(27): 2805-2816.
[33] Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J]. N Engl J Med, 2006, 355(14): 1432-1444.
[34] Dixon JA, Oliver SC, Olson JL, et al. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration [J]. Expert Opin Investig Drugs, 2009, 18(10): 1573-1580.
[35] Wells JA, Glassman AR, Ayalaet AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema [J]. N Engl J Med, 2015, 372(13): 1193-1203.
[36] Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD [J]. N Engl J Med, 2011, 364(20): 1966-1967.
[37] Kim SY, Yoon MH, Chin HS. Changes in the ganglion cell-inner plexiform layer after consecutive intravitreal injections of anti-vascular endothelial growth factor in age-related macular degeneration patients [J]. Korean J Ophthalmol, 2020, 34(1): 11-18.
[38] Filek R, Hooper P, Sheidow TG, et al. Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients [J]. Clin Ophthalmol, 2019, 13: 1087-1096. doi: 10.2147/OPTH.S199758. eCollection 2019.
[39] Cao R, Xue Y, Hedlund EM, et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy [J]. Proc Natl Acad Sci USA, 2010, 107(2): 856-861.
[40] Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors [J]. PLoS One, 2008, 3(11): e3554. doi: 10.1371/journal.pone.0003554.
[41] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995, 1(1): 27-31.
[42] Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 [J]. Nat Med, 2003, 9(5): 604-613.
[43] Lu H, Xu X, Zhang M, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs [J]. Proc Natl Acad Sci USA, 2007, 104(29): 12140-12145.
[44] Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study [J]. Wound Repair Regen, 1999, 7(3): 141-147.
[45] Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature [J]. Proc Natl Acad Sci USA, 2002, 99(16): 10730-10735.
[46] Brakenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice [J]. Circ Res, 2004, 94(12): 1579-1588.
[47] Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases [J]. Nat Rev Drug Discov, 2010, 9(2): 107-115.
[48] Cao Y. Angiogenesis modulates adipogenesis and obesity [J]. J Clin Invest, 2007, 117(9): 2362-2368.
[49] Cao Y. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity [J]. Cell Metab, 2013, 18(4): 478-489.
[50] Xue Y, Petrovic N, Cao R, et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation [J]. Cell Metab, 2009, 9(1): 99-109.
[51] Seki T, Hosaka K, Lim S, et al. Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat [J]. Nat Commun, 2016, 7: 12152. doi: 10.1038/ncomms12152.
[52] Fischer C, Seki T, Lim S, et al. A miR-327-FGF10-FGFR2-mediated autocrine signaling mechanism controls white fat browning [J]. Nat Commun, 2017, 8(1): 2079. doi: 10.1038/s41467-017-02158-z.
[53] De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis [J]. N Engl J Med, 2012, 367(25): 2385-2395.
[54] Tindall EA, Fox DA. Treatment for rheumatic disorders [J]. N Engl J Med, 2006, 354(12): 1322-1323.
[55] Dinarello CA. Interleukin-1beta and the autoinflammatory diseases [J]. N Engl J Med, 2009, 360(23): 2467-2470.
[56] Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis [J]. N Engl J Med, 2002, 347(26): 2104-2110.
[57] Pang J, Xu F, Aondio G, et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19 [J]. Nat Commun, 2021, 12(1): 814. doi: 10.1038/s41467-021-21085-8.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed